Cobinamide compounds as a cyanide, sulfide, or methane-thiol antidote
Methods and compositions for treating cyanide, sulfide, or methane-thiol exposure in a subject. The compositions may include one or more cobinamide compounds, such as an amino-tetrazole-cobinamide and/or a di-(amino-tetrazole)-cobinamide.
1. A method for ameliorating one or more symptoms associated with cyanide exposure, sulfide exposure, or methane thiol exposure in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising an effective amount of one or more cobinamide compounds; wherein the one or more cobinamide compounds is selected from the group consisting of an amino-tetrazole-cobinamide, a di-(amino-tetrazole)-cobinamide, an acetyl-tetrazole-cobinamide, and a di-(acetyl-tetrazole)-cobinamide.
2. The method of claim 1 , wherein the amino-tetrazole-cobinamide comprises 5-amino-tetrazole-cobinamide.
3. The method of claim 1 , wherein the di-(amino-tetrazole)-cobinamide comprises di-(5-amino-tetrazole)-cobinamide.
4. The method of claim 1 , wherein the acetyl-tetrazole-cobinamide comprises 5-acetyl-tetrazole-cobinamide.
5. The method of claim 1 , wherein the di-(acetyl-tetrazole)-cobinamide comprises di-(5-acetyl-tetrazole)-cobinamide.
6. The method of claim 1 , wherein the effective amount of the one or more cobinamide compounds is about 8 mg/kg to about 24 mg/kg.
7. The method of claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier to facilitate the amelioration of one or more symptoms.
8. The method of claim 1 , wherein the pharmaceutical composition is a sterile solution or a sterile suspension.
9. A pharmaceutical composition comprising one or more cobinamide compounds, wherein the one or more cobinamide compounds is selected from the group consisting of an amino-tetrazole-cobinamide, a di-(amino-tetrazole)-cobinamide, an acetyl-tetrazole-cobinamide, and a di-(acetyl-tetrazole)-cobinamide.
10. The pharmaceutical composition of claim 9 , wherein the amino-tetrazole-cobinamide comprises 5-amino-tetrazole-cobinamide.
11. The pharmaceutical composition of claim 9 , wherein the di-(amino-tetrazole)-cobinamide comprises di-(5-amino-tetrazole)-cobinamide.
12. The pharmaceutical composition of claim 9 , wherein the acetyl-tetrazole-cobinamide comprises 5-acetyl-tetrazole-cobinamide.
13. The pharmaceutical composition of claim 9 , wherein the di-(acetyl-tetrazole)-cobinamide comprises di-(5-acetyl-tetrazole)-cobinamide.
14. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
15. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is a sterile solution or a sterile suspension.
16. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is formulated for intramuscular delivery.